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Abstract
Background: Physicians involved in primary prevention are key players in CVD risk control strategies, but the
expected reduction in CVD risk that would be obtained if all patients attending primary care had their risk factors
controlled according to current guidelines is unknown. The objective of this study was to estimate the excess risk
attributable, firstly, to the presence of CVD risk factors and, secondly, to the lack of control of these risk factors in
primary prevention care across Europe.
Methods: Cross-sectional study using data from the European Study on Cardiovascular Risk Prevention and
Management in Daily Practice (EURIKA), which involved primary care and outpatient clinics involved in primary
prevention from 12 European countries between May 2009 and January 2010. We enrolled 7,434 patients over 50
years old with at least one cardiovascular risk factor but without CVD and calculated their 10-year risk of CVD
death according to the SCORE equation, modified to take diabetes risk into account.
Results: The average 10-year risk of CVD death in study participants (N = 7,434) was 8.2%. Hypertension,
hyperlipidemia, smoking, and diabetes were responsible for 32.7 (95% confidence interval 32.0-33.4), 15.1 (14.8-15.4),
10.4 (9.9-11.0), and 16.4% (15.6-17.2) of CVD risk, respectively. The four risk factors accounted for 57.7% (57.0-58.4) of
CVD risk, representing a 10-year excess risk of CVD death of 5.66% (5.47-5.85). Lack of control of hypertension,
hyperlipidemia, smoking, and diabetes were responsible for 8.8 (8.3-9.3), 10.6 (10.3-10.9), 10.4 (9.9-11.0), and 3.1%
(2.8-3.4) of CVD risk, respectively. Lack of control of the four risk factors accounted for 29.2% (28.5-29.8) of CVD risk,
representing a 10-year excess risk of CVD death of 3.12% (2.97-3.27).
Conclusions: Lack of control of CVD risk factors was responsible for almost 30% of the risk of CVD death among
patients participating in the EURIKA Study.
Keywords: cardiovascular disease, mortality, risk factors, control, SCORE
Background
Hypertension, dyslipidemia, smoking and diabetes melli-
tus are established modifiable causes of cardiovascular
(CVD) disease [1,2]. However, in spite of effective inter-
ventions and widespread knowledge, the prevalence of
CVD risk factors in Western populations is high and the
proportion of patients with controlled risk factors is low
[3,4]. It is clear that we need more effective translation
strategies at the individual and the population levels to
control the CVD disease epidemic.
Physicians involved in primary prevention are key
players in CVD risk control strategies. Risk scoring
instruments have been developed to help practitioners
assess the overall CVD risk of patients and guide clinical
interventions. The European Society of Cardiology has
promoted the use of the Systematic Coronary Risk Eva-
luation (SCORE) equation to estimate the 10-year risk
of CVD death, with separate equations for high and low
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risk regions in Europe [1,5]. It may be important for
physicians to consider the reduction in CVD risk that
would be obtained if all patients had their risk factors
controlled according to current guidelines. As a conse-
quence, we used data from the European Study on CVD
Risk Prevention and Management in Daily Practice
(EURIKA), a cross-sectional study of primary care and
specialized outpatient clinics involved in primary pre-
vention in Europe, to calculate the estimated excess risk
attributable to the presence and to the lack of control of
traditional CVD risk factors in usual clinical care in
Europe.
Methods
Study population
The EURIKA Study used a cross-sectional design to
estimate the degree of control of traditional CVD risk
factors in clinical practice across Europe (ClinicalTrials.
gov identifier, NCT00882336) [6]. EURIKA was con-
ducted in 12 European countries (Austria, Belgium,
France, Germany, Greece, Norway, Russia, Spain, Swe-
den, Switzerland, Turkey and the United Kingdom)
from May 2009 to January 2010. Approximately 60 phy-
sicians per country were selected at random from the
OneKey database, a large database containing informa-
tion on the characteristics of physicians in participating
countries. Physicians were selected after stratification by
age, sex and specialty, among practitioners involved in
CVD disease prevention in primary care centres or out-
patient clinics [6].
Study participants were selected at random among
those patients attending the clinics of participating phy-
sicians during the study period who were 50 years of
age or older, had no clinically manifest CVD disease,
and had at least one traditional CVD risk factor (hyper-
tension, dyslipidemia, diabetes, obesity, or tobacco con-
sumption). A total of 12,292 patients were invited to
participate, of whom 7,641 (60.1%) fulfilled the inclusion
criteria and consented to take part in the study. We
excluded 3 patients who were younger than 50 years of
age, 102 patients missing data on smoking, 13 patients
missing blood pressure, 69 patients missing cholesterol
levels, and 20 patients missing HbA1 c levels. The final
sample size was 7,434 patients. The study protocol was
approved by the appropriate clinical research ethics
committees in each participating country. All patients
provided written informed consent.
Assessment of CVD risk factors
Patient information was collected from clinical records,
from a standardized interview and physical exam, and
from laboratory analyses of blood samples obtained dur-
ing the study visit. Information on smoking was
obtained from patient interviews. Blood pressure was
determined at the time of the visit. A 12 h-fasting blood
sample was obtained on the day of physical examination
or, if not possible, on the following day. Except for
blood samples from Russian centers, laboratory assays
were conducted at a central study laboratory in Belgium
for analysis (The Bio Analytical Research Corporation,
http://www.barclab.com). Russian samples were analyzed
at a local laboratory in Russia calibrated and standar-
dized to the central study laboratory. Total cholesterol
was measured by the CHOD-PAP method (Roche P-
Modular) and glycosylated haemoglobin (HbA1c) was
measured by ion-exchange (high-performance liquid
chromatography/Menarini 8160). A 10% random sample
of all study centres in each country underwent a site
visit for data monitoring and quality audit.
Definitions and treatment goals for cardiovascular risk
factors
Definitions of CVD risk factors and treatment goals
were based on the guidelines of the Fourth European
Joint Task Force [1]. Prevalent hypertension was defined
as a diagnosis of hypertension in the clinical record, cur-
rent use of antihypertensive medication, or a measured
blood pressure ≥ 140/90 mmHg (130/80 in patients with
diabetes) at the study visit. Treatment target for hyper-
tensive patients was a blood pressure < 140/90 mmHg
(130/80 mmHg in patients with diabetes). Prevalent dys-
lipidemia was defined as a diagnosis of dyslipidemia in
the clinical record, current use of lipid lowering medica-
tion, or a total cholesterol level ≥ 5 mmol/L (4.5 mmol/
L in patients with diabetes) at the study visit. Treatment
target for dyslipidemic patients was a total cholesterol <
5 mmol/L (4.5 in patients with diabetes). Prevalent dia-
betes was defined as a diagnosis of diabetes in the clini-
cal record, current use of antidiabetic medication, or an
HbA1 c level ≥ 6.5% at the study visit [7]. Treatment
target for patients with diabetes was an HbA1 c < 6.5%.
Statistical methods
We estimated the 10-year risk of fatal CVD disease for
each patient based on the SCORE equation using data
on age, sex, current smoking, total cholesterol and sys-
tolic blood pressure measured at the study visit [5]. We
used the equation developed for low-risk regions for
patients in Belgium, France, Greece, Spain and Switzer-
land, and the equation for high-risk regions for patients
in Austria, Germany, Norway, Russia, Sweden, Turkey
and the United Kingdom [5]. Since the SCORE equation
does not incorporate diabetes as a risk factor, we modi-
fied the estimated 10-year risks for patients with dia-
betes assuming that the relative risks associated with
diabetes were 1.89 and 2.59 for coronary events in men
and women, respectively, and 2.16 and 2.83 for non-cor-
onary CVD events in men and women, respectively [8].
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To estimate risks attributable to each CVD risk factor,
we recalculated the estimated 10-year risks of fatal CVD
disease assuming that participants with dyslipidemia had
the average total cholesterol levels of patients without
dyslipidemia; that patients with hypertension had the
average systolic blood pressure of patients with normal
blood pressure (< 120 mmHg); that current smokers did
not smoke; and that patients with diabetes did not have
diabetes (that is, equal to their SCORE risk without
multiplication by the relative risk for diabetes). Similarly,
to estimate the risks attributable to lack of control of
each CVD risk factor, we recalculated the estimated 10-
year risks of fatal CVD disease assuming that partici-
pants with uncontrolled dyslipidemia were at target
levels of total cholesterol; that patients with uncon-
trolled hypertension were at target levels of systolic
blood pressure; that current smokers did not smoke;
and that the risk of CVD death for diabetic patients
increases by 18% for each increase in 1 percentage point
in HbA1 c above target HbA1 c level [9].
Excess risks were calculated for each participant as the
absolute difference between 10-year SCORE risks esti-
mated under the observed levels of risk factors and the
absence (or the control) of risk factors. Attributable
risks for each participant were calculated for each parti-
cipant as the ratio between the excess risk and the 10-
year SCORE risk. Predicted marginal means of estimated
excess and attributable risks were calculated using linear
mixed models adjusted for age, sex, and country, with
random intercepts for study physician. 95% confidence
intervals for predicted marginal means were calculated
using the delta method. Statistical analyses were per-
formed using STATA version 11 http://www.stata.com.
Results
The average (SD) age of study participants was 63.2
(9.0) years and the proportion of women was 51.8%
(Table 1). The proportions of patients who were current
smokers, hypertensive, dyslipidemic, or diabetic were
21.4%, 80.5%, 89.4%, and 29.6%, respectively. The pro-
portions of patients with uncontrolled hypertension,
uncontrolled dyslipidemia, and uncontrolled diabetes
were 53.5% (66.5% of hypertensive patients), 69.8%
(78.0% of dyslipidemic patients), and 19.0% (64.3% of
patients with diabetes), respectively. The average 10-year
risk of CVD death was 8.2%: 11.96% for men in high-
risk countries, 7.08% for men in low-risk countries,
7.45% for women in high-risk countries, and 5.62% for
women in low-risk countries.
Hypertension, dyslipidemia, smoking, and diabetes
were responsible for 32.7 (32.0-33.4), 15.1 (14.8-15.4),
10.4 (9.9-11.0), and 16.4% (15.6-17.2) of CVD risk,
respectively (Table 2). These risk factors accounted for
57.7% (57.0-58.4) of CVD risk, with relatively little
between country variability (between-country range 52.6
to 61.6%). The 10-year absolute excess risks of CVD
death attributable to hypertension, hyperlipidemia,
smoking, and diabetes were 3.49 (95% confidence inter-
val 3.34-3.63), 1.14 (1.08-1.19), 0.92 (0.85-0.99), and
2.25% (2.12-2.39), respectively (Figure 1 and Additional
File 1: Table S1). The absolute excess risk attributable
to the four risk factors combined was 5.66% (5.47-5.85)
(Figure 2), with a between-country range of 3.06 to
4.65% among low-risk countries and 5.39 to 8.12%
among high-risk countries.
Lack of control of hypertension, dyslipidemia, smoking,
and diabetes were responsible for 8.8 (8.3-9.3), 10.6
(10.3-10.9), 10.4 (9.9-11.0), and 3.1% (2.8-3.4) of CVD
risk, respectively (Table 3). Lack of control of the com-
bination of these risk factors accounted for 29.2% (28.5-
29.8) of CVD risk, with a between-country range of 22.1
to 34.0%. The 10-year absolute excess risks of CVD
death attributable to lack of control of hypertension,
hyperlipidemia, smoking, and diabetes were 1.42 (1.31-
1.53), 0.92 (0.87-0.96), 0.92 (0.85-0.99), and 0.41% (0.37-
0.46), respectively (Figure 1 and Additional File 1: Table
S2’). The excess risk attributable to lack of control of 4
risk factors was 3.12% (2.97-3.27) (Figure 2), with a
between-country range of 1.33 to 2.50% among low-risk
countries and 2.87 to 4.26% among high-risk countries.
Absolute excess risks were particularly high among
patients with current estimated risk ≥ 10% (excess risks
attributable to the presence and to the lack of control of
risk factors of 14.50 and 9.41%, respectively), among
patients with diabetes (10.52 and 5.73%, respectively),
among patients ≥ 65 years of age (9.76 and 5.12%,
respectively), and among current smokers (9.09 and
6.69%, respectively) (Additional File 1: Table S3).
Discussion
Hypertension, dyslipidemia, smoking and diabetes
explained 57.7% of estimated risk of CVD death of
patients 50 years of age and older with at least one
CVD risk factor who attended primary and specialty
clinics involved in primary prevention across Europe in
the EURIKA study. Eliminating these risk factors would
translate in an absolute reduction of 5.66% in the 10-
year risk of CVD death. Even though EURIKA patients
were under medical care, lack of control of traditional
risk factors was common, and explained almost 30% of
estimated risk. Control of hypertension, dyslipidemia,
smoking and diabetes would reduce the estimated 10-
year risk of CVD death by 3.12%. Absolute risk reduc-
tions through elimination or control of hypertension,
dyslipidemia, smoking and diabetes would be particu-
larly large in patients with high overall risk, in patients
with diabetes, in elderly patients, and in current
smokers.
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Table 1 Characteristics of study participants, EURIKA Study 2009 - 2010
Low risk countries High risk countries
Overall Belgium France Greece Spain Switzerland Austria Germany Norway Russia Sweden Turkey UK
N 7,434 (100.0) 630 (8.1) 555 (7.5) 619 (8.3) 631 (8.5) 632 (8.5) 604 (8.1) 641 (8.6) 594 (8.0) 593 (8.0) 614 (8.3) 655 (8.8) 666 (9.0)
Age (years) 63.2 (9.0) 64.6 (8.9) 64.2 (8.8) 62.9 (8.9) 63.1 (9.8) 65.3 (9.9) 61.8 (8.6) 65.5 (8.8) 62.9 (8.5) 58.3 (7.3) 64.9 (8.6) 59.4 (7.6) 65.0 (8.9)
Sex
Men 3,584 (48.2) 309 (49.1) 301 (54.2) 284 (45.9) 323 (51.2) 336 (53.2) 288 (47.7) 313 (48.8) 292 (49.2) 184 (31.0) 307 (50.0) 308 (47.0) 339 (50.9)
Women 3,850 (51.8) 321 (50.9) 254 (45.8) 335 (54.1) 308 (48.8) 296 (46.8) 316 (52.3) 328 (51.2) 302 (50.8) 409 (69.0) 307 (50.0) 347 (53.0) 327 (49.1)
Smoking
Never 3,832 (51.6) 379 (60.2) 316 (56.9) 300 (48.5) 370 (58.6) 315 (49.8) 298 (49.3) 332 (51.8) 213 (35.9) 351 (59.2) 300 (48.9) 348 (53.1) 310 (46.6)
Current 1,588 (21.4) 102 (16.2) 90 (16.2) 209 (33.8) 107 (17.0) 137 (21.7) 144 (23.8) 107 (16.7) 173 (29.1) 150 (25.3) 103 (16.8) 156 (23.8) 110 (16.5)
Former 2,014 (27.1) 149 (23.7) 149 (26.9) 110 (17.8) 154 (24.4) 180 (28.5) 162 (26.8) 202 (31.5) 208 (35.0) 92 (15.5) 211 (34.4) 151 (23.1) 246 (36.9)
SBP (mmHg)* 135.0 (16.6) 132.6 (14.4) 133.2 (13.2) 129.8 (14.4) 133.9 (16.8) 136.1 (16.0) 135.3 (17.6) 135.3 (17.2) 136.6 (16.1) 136.5 (17.5) 140.1 (17.2) 134.4 (19.3) 136.3 (15.9)
DBP (mmHg)* 80.9 (9.9) 78.7 (8.2) 77.8 (8.9) 79.9 (8.8) 78.8 (10.2) 81.6 (10.0) 82.8 (9.7) 80.5 (9.5) 82.2 (9.9) 84.2 (10.3) 82.3 (9.7) 82.4 (11.6) 79.1 (9.9)
Hypertension 5,984 (80.5) 496 (78.7) 443 (79.8) 451 (72.9) 473 (75.0) 511 (80.9) 473 (78.3) 569 (88.8) 478 (80.5) 488 (82.3) 553 (90.1) 500 (76.3) 549 (82.4)
Uncontrolled 3,975 (53.5) 307 (48.7) 262 (47.5) 262 (42.4) 298 (47.3) 350 (55.4) 324 (53.7) 382 (59.6) 351 (59.1) 332 (56.1) 392 (64.0) 366 (56.0) 349 (52.5)
hypertension
Tot. chol. (mmol/l)* 5.4 (1.1) 5.2 (1.0) 5.5 (1.1) 5.5 (1.1) 5.5 (1.1) 5.4 (1.1) 5.6 (1.2) 5.6 (1.1) 5.5 (1.1) 5.9 (1.2) 5.5 (1.2) 5.3 (1.1) 5.1 (1.2)
Dyslipidemia 6,646 (89.4) 560 (88.9) 508 (91.5) 582 (94.0) 581 (92.1) 568 (89.9) 544 (90.1) 577 (90.0) 548 (92.3) 532 (89.7) 550 (89.6) 509 (77.7) 587 (88.1)
Uncontrolled 5,185 (69.8) 376 (59.7) 401 (72.3) 438 (70.8) 459 (72.7) 433 (68.5) 457 (75.7) 486 (75.8) 436 (76.4) 484 (81.6) 424 (69.1) 446 (68.1) 345 (51.8)
dyslipidemia
HbA1 c (%)* 6.1 (1.0) 5.9 (0.9) 5.9 (0.9) 6.0 (1.0) 6.0 (1.1) 6.0 (0.9) 6.0 (0.9) 6.1 (0.9) 5.9 (0.9) 6.3 (1.0) 6.1 (1.0) 6.5 (1.6) 6.0 (0.9)
Diabetes 2,200 (29.6) 182 (28.9) 144 (26.0) 189 (30.5) 190 (30.1) 205 (32.4) 156 (25.8) 255 (39.8) 145 (24.4) 143 (24.1) 171 (27.9) 246 (37.6) 174 (26.1)
Uncontrolled 1,415 (19.0) 98 (15.6) 89 (16.0) 110 (17.8) 117 (18.5) 121 (19.2) 94 (15.6) 140 (21.8) 86 (14.5) 117 (19.7) 131 (21.3) 191 (29.2) 121 (18.2)
diabetes
10-y CVD risk (%)* 8.2 (9.8) 6.0 (7.2) 5.8 (6.3) 5.7 (6.7) 6.0 (6.7) 8.2 (10.1) 9.1 (10.9) 12.8 (13.2) 9.5 (9.8) 6.2 (7.7) 11.7 (12.4) 7.4 (9.3) 9.9 (10.6)
< 5% 3,690 (49.6) 370 (58.7) 331 (59.6) 383 (61.9) 384 (60.9) 326 (51.6) 282 (46.7) 194 (30.3) 238 (40.1) 369 (62.2) 204 (33.2) 360 (55.0) 249 (37.4)
5-10% 1,824 (24.5) 158 (25.1) 136 (24.5) 131 (21.2) 132 (20.9) 147 (23.3) 150 (24.8) 172 (26.8) 164 (27.6) 118 (19.9) 158 (25.7) 157 (24.0) 201 (30.2)
≥ 10% 1,920 (25.8) 102 (16.2) 88 (15.9) 105 (17.0) 115 (18.2) 159 (25.2) 172 (28.5) 275 (42.9) 192 (32.3) 106 (17.9) 252 (41.0) 138 (21.1) 216 (32.4)
Values in table are number (%) or mean (SD) where noted by *.
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Table 2 Cardiovascular risk attributable to traditional cardiovascular risk factors (%), EURIKA Study 2009 - 2010
Low risk countries High risk countries
Overall Belgium France Greece Spain Switzerland Austria Germany Norway Russia Sweden Turkey UK
Hypertension 32.7 29.9 30.1 26.1 30.9 33.1 32.4 33.5 34.3 37.1 38.8 32.7 33.5
(32.0-33.4) (27.5-32.3) (27.5-32.7) (23.6-28.6) (28.4-33.3) (30.8-35.5) (29.9-34.9) (31.1-35.9) (31.7-36.8) (34.8-39.3) (36.3-41.3) (30.3-35.1) (31.1-35.9)
Dyslipidemia 15.1 11.2 15.3 14.4 14.7 14.2 17.6 17.3 16.8 19.2 16.0 13.3 11.9
(14.8-15.4) (10.0-12.3) (14.1-16.5) (13.2-15.9) (13.5-15.9) (13.0-15.3) (16.5-18.8) (16.1-18.4) (15.6-18.1) (18.1-20.3) (14.8-17.2) (12.2-14.5) (10.8-13.0)
Smoking 10.4 8.5 8.4 16.4 8.3 11.6 11.0 9.4 14.1 10.3 9.1 9.7 8.8
(9.9-11.0) (6.7-10.4) (6.4-10.4) (14.5-18.3) (6.5-10.2) (9.7-13.4) (9.1-12.8) (7.6-11.2) (12.2-16.0) (8.5-12.1) (7.2-11.0) (7.9-11.5) (7.0-10.6)
Diabetes 16.4 15.7 13.9 17.1 16.7 17.5 14.7 21.5 13.6 14.5 15.1 21.8 13.7
(15.6-17.2) (12.9-18.5) (10.8-16.9) (14.2-20.1) (13.8-19.5) (14.7-20.3) (11.8-17.7) (18.7-24.3) (10.6-16.6) (11.9-17.2) (12.1-18.1) (19.0-24.6) (10.8-16.5)
All risk factors 57.7 52.6 53.9 56.5 55.2 58.7 57.9 61.0 60.6 61.6 61.1 59.4 54.1
(57.0-58.4) (50.3-54.9) (51.4-56.4) (54.1-58.9) (52.9-57.6) (56.4-61.0) (55.5-60.3) (58.6-63.3) (58.1-63.0) (59.4-63.8) (58.7-63.6) (57.0-61.7) (51.8-56.4)
Values in Table are % (95% confidence interval).
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The prevalence of CVD risk factors in the EURIKA
population was high, partly as a consequence of includ-
ing patients with at least one traditional CVD risk factor
(hypertension, dyslipidemia, smoking, diabetes or obe-
sity) [6]. Among subjects 50 years of age or older in
Western societies, however, the prevalence of these risk
factors is very high [10-13], making the EURIKA find-
ings applicable to a wide segment of the population
attending general medical care. In addition, a large frac-
tion of EURIKA patients did not reach target levels of
control [1]. These findings are consistent with earlier
surveys showing highly inadequate risk factor control in
patients with and without established CVD disease
[3,14-18]. For instance, the EUROASPIRE III Survey,
conducted in 2006 - 2007 among patients without a his-
tory of atherosclerotic disease who were treated with
antihypertensive, lipid-lowering, or antidiabetic drugs in
general practice in 12 European countries, found that
73.7% of patients using antihypertensive medications
had blood pressure above 140/90 mmHg (above 130/80
mmHg among patients with diabetes), 69.4% of patients
using lipid-lowering medications had total cholesterol
above 5.0 mmol/L (above 4.5 mmol/L among patients
with diabetes), and 60.1% of self-reported patients with
diabetes had HbA1 c above 6.1% [3]. Our analysis of the
EURIKA Study extends these findings to show that lack
of risk factor control is responsible for a substantial
excess risk among patients already under clinical care,
highlighting the need for more effective translation of
evidence-based guidelines into routine care.
Hypertension has been identified as the leading risk
factor for mortality and the third cause of disability-
Figure 1 Estimated 10-year risk of cardiovascular death calculated at current levels of blood pressure, total cholesterol, smoking, and
diabetes (red line), assuming risk factors at control level (blue), and assuming absence of risk factors (black).
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adjusted life-years worldwide [19,20]. In the EURIKA
population, elevated blood pressure was responsible for
32.7% of CVD risk. Indeed, our analyses likely underesti-
mate the contribution of elevated blood pressure to
CVD risk as we did not consider the excess risk contrib-
uted by patients with prehypertension [20]. Even though
the EURIKA population was under medical surveillance
and 68.5% of study patients were receiving antihyperten-
sive medications, over 50% of EURIKA patients had
measured levels of blood pressure above 140/90 mmHg.
Control of blood pressure levels to target levels would
reduce the estimated risk by 8.8%, with particularly high
gains in Sweden, Russia, and Turkey, although there
may be a degree of resistant hypertension that even
after aggressive management by the clinician might not
result in blood pressure being brought back to target.
Beyond the well-known challenges for control of hyper-
tension in clinical settings [21], lowering blood pressure
to normotensive levels in the population will require
intensive public health action to control the obesity epi-
demic and to promote healthy eating and exercise habits
in the general population [19,20]. Our analysis of the
EURIKA data emphasizes the need to combine clinic-
based and population strategies to curb high blood pres-
sure-related risk.
Dyslipidemia was responsible for 15.1% of CVD death
risk in the EURIKA population, and achieving control
levels of 5 mmol/L in all EURIKA participants would
reduce the estimated CVD death risk by 10.6%. The
impact of dyslipidemia was particularly high in Russia, a
country with very high average cholesterol levels and
with low rates of control. As for hypertension, control
Figure 2 Estimated 10-year risk of cardiovascular death calculated at current levels of risk factors (red line), assuming risk factors at
control level (blue), and assuming absence of risk factors (black).
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Table 3 Cardiovascular risk attributable to lack of control of traditional cardiovascular risk factors (%), EURIKA Study 2009 - 2010
Low risk countries High risk countries
Overall Belgium France Greece Spain Switzerland Austria Germany Norway Russia Sweden Turkey UK
Hypertension 8.8 6.0 5.4 5.0 8.8 9.0 9.6 9.9 9.5 11.2 11.6 10.2 8.7
(8.3-9.3) (4.4-7.7) (3.6-7.2) (3.3-6.8) (7.0-10.5) (7.3-10.6) (7.9-11.4) (8.2-11.5) (7.7-11.3) (9.6-12.8) (9.8-13.4) (8.5-11.9) (7.0-10.4)
Dyslipidemia 10.6 7.2 10.6 10.0 10.1 9.9 12.5 12.7 11.6 14.3 11.2 9.5 7.8
(10.3-10.9) (6.2-8.1) (9.5-11.6) (8.9-11.0) (9.1-11.1) (8.9-10.9) (11.5-13.6) (11.7-13.7) (10.6-12.7) (13.3-15.3) (10.2-12.3) (8.5-10.5) (6.9-8.8)
Smoking 10.4 8.5 8.4 16.4 8.3 11.6 11.0 9.4 14.1 10.3 9.1 9.7 8.8
(9.9-11.0) (6.7-10.4) (6.4-10.4) (14.5-18.3) (6.5-10.2) (9.7-13.4) (9.1-12.8) (7.6-11.2) (12.2-16.0) (8.5-12.1) (7.2-11.0) (7.9-11.5) (7.0-10.6)
Diabetes 3.1 2.2 2.3 2.6 3.4 2.5 2.5 2.5 2.4 3.3 3.6 6.6 2.7
(2.8-3.4) (1.2-3.2) (1.3-3.4) (1.5-3.6) (2.4-4.4) (1.5-3.5) (1.5-3.5) (1.5-3.5) (1.3-3.4) (2.4-4.2) (2.5-4.6) (5.6-7.6) (1.7-3.7)
All risk factors 29.2 22.1 24.1 30.0 27.2 29.4 31.2 30.4 33.0 34.0 31.3 31.8 25.5
(28.5-29.8) (19.9-24.3) (21.7-26.5) (27.7-32.3) (25.0-29.5) (27.2-31.6) (28.9-33.5) (28.2-32.7) (30.7-35.4) (31.8-36.2) (29.0-33.6) (29.6-34.0) (23.3-27.7)
Values in Table are % (95% confidence interval).
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rates for dyslipidemia are low even with the availability
of highly effective and safe interventions to reduce cho-
lesterol levels [22]. Furthermore, since the benefits of
cholesterol lowering therapies are independent of pre-
treatment cholesterol levels or other patient characteris-
tics [22,23], cholesterol lowering therapies could be used
to achieve specific reductions in cholesterol levels
(instead of targeting pre-specified levels of control) as a
core component of high-risk patient management. The
high proportion of patients with uncontrolled dyslipide-
mia in the EURIKA population and the associated
excess risk further call for added clinical and public
health efforts to control cholesterol levels.
With a proportion of current smokers of 21.4% in the
EURIKA population, smoking accounted for 10.4% of
CVD risk, with particularly high attributable risks in
Greece and Norway. Furthermore, since smoking habits
were identified by questionnaire without confirmation
by objective biomarkers, it is likely that the proportion
of current smokers and the associated attributable risk
have been underestimated [24]. The benefits of quitting
smoking are well documented and all current smokers
should be encouraged to quit [25,26]. Primary practices
and specialized clinics are important checkpoints in this
process [26], although population strategies are needed
to favor a smoke-free environment and an appropriate
atmosphere for sustained quitting.
Diabetes was responsible for 16.4% of CVD risk in
the EURIKA population, but control of diabetes would
only reduce CVD risk by 3.1%. Excess risks associated
with diabetes were particularly high in Turkey and
Germany. While diabetes is a strong independent risk
factor for CVD, the benefits of intensive glycemic con-
trol on macrovascular disease outcomes and mortality
are controversial. Indeed, recent trials have shown
either no significant reduction in CVD outcomes or
increased mortality with intensive glycemic control
[27]. In our analysis, we assumed based on observa-
tional data that the risk of CVD death for diabetic
patients increases by 18% for each 1 percentage point
increase in HbA1 c above target HbA1 c level [9], but
this assumption will need to be modified as additional
evidence accumulates on the impact of intense glyce-
mic control on CVD outcomes and we develop more
reliable estimates of the benefit of glucose control on
macrovascular CVD outcomes. While attaining glyce-
mic control targets is still a key objective of manage-
ment of patients with diabetes, our data also show that
substantial risk benefits can be realized in patients
with diabetes by control of other cardiovascular risk
factors. Ultimately, however, the main approach to dia-
betes risk control should be based on primary preven-
tion of diabetes through control of the obesity
epidemic and adoption of healthy lifestyles.
Our estimates of attributable risks in the EURIKA
population rely on a series of assumptions. First, SCORE
equations were developed to have better calibration for
European populations, but there is concern that the
SCORE equation may overestimate risk in many Wes-
tern European countries with decreasing secular trends
in CVD mortality as well as in elderly patients [28].
Calibration of the SCORE equation to country-specific
CVD mortality rates has been advocated [29], but joint
data on CVD risk factors and mortality rates in country-
wide representative population samples were not avail-
able in most EURIKA countries. Conversely, the SCORE
equation may underestimate risk in Russia and other
Eastern European countries that are experiencing extre-
mely high rates of CVD mortality [30,31]. Furthermore,
the SCORE equation may underestimate risk in patients
with certain risk factors not included in the equation,
such as those with a sedentary lifestyle, central obesity,
a family history of premature CVD, or with the presence
of subclinical atherosclerosis [1]. Country specific cali-
bration or recalibration of equations to current CVD
death rates will change the estimates, although we
notice that the proportion of CVD risk attributable to
each risk factor and overall is relatively constant across
countries, suggesting that the main conclusions of our
analyses are likely to hold under revised risk equations.
Second, the EURIKA population was already under
clinical care and a high proportion of EURIKA patients
were taking medications to lower blood pressure
(68.5%), lipids (43.2%) or glucose levels (23.4%). Since
we do not have pre-medication data collected under
standardized conditions, we could not calculate the full
impact of risk factors or the benefits of clinical care in
terms of risk reduction. Third, while the cohorts used to
derive the original SCORE equation included partici-
pants with diabetes, the equation did not incorporate
diabetes as a predictor due to differences in diabetes
definition and ascertainment across cohorts [5]. Since
the prevalence of diabetes in the EURIKA population
was much higher than the prevalence of diabetes in the
SCORE populations, we considered that it was impor-
tant to account for diabetes as an independent risk fac-
tor and thus increased the risk of patients with diabetes
by a factor derived from a large pooled analysis of dia-
betes risk [8]. This approach may result in some overes-
timation of overall risk and of the contribution of
diabetes in our study, but is likely a better approxima-
tion to the true underlying risk than the original SCORE
equation in a population with high diabetes prevalence.
Finally, the SCORE equation is restricted to predict
10-year risk of fatal CVD, and thus underestimate the
burden of CVD by excluding non-fatal events and
events occurring after 10 years of follow-up. Even with
these sources of uncertainty, our analyses indicate that 4
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well-established, preventable and controllable risk fac-
tors were responsible for almost 60% of estimated CVD
risk and that lack of control of these risk factors accord-
ing to clinical guidelines was responsible for almost 30%
of CVD risk, a failure of both clinical medicine and pub-
lic health.
Conclusions
In the EURIKA study, lack of control of CVD risk fac-
tors was responsible for almost 30% of CVD mortality
risk. Systematic monitoring of CVD risk factor levels
and of SCORE risk estimates can thus help practitioners
understand the implications of risk factor management
and control in their patient populations. Patients with
high estimated risk, patients with diabetes, elderly
patients and current smokers would show substantial
absolute reductions in estimated risk by attaining target
control levels. These findings are in agreement with cur-
rent guidelines to direct intensive therapy to patients at
high estimated risk and validate the use of SCORE or
other risk equations to manage risk reduction [1,2]. The
clinical approach to patients with low absolute risk,
including young patients with high levels of risk factors,
is more complex. Our data indicate that both a clinical
and a public health approach are needed to maximize
CVD prevention and call for added efforts to develop
translational approached that effectively implement pre-
vention strategies in individual patients and in popula-
tion settings.
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